NAMSW
NewAmsterdam Pharma Company N.V. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.08
52W High
$30.45
52W Low
$9.32
50-Day MA
$22.60
200-Day MA
$22.86
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical firm dedicated to advancing innovative therapies for cardiometabolic diseases, with a particular focus on dyslipidemia, a key contributor to cardiovascular risks. The company is leveraging a strong R&D framework to evaluate its novel drug candidates, strategically positioning itself for potential regulatory approvals. With a commitment to addressing significant unmet medical needs in this critical therapeutic area, NewAmsterdam seeks to enhance patient outcomes and deliver long-term value to its shareholders, presenting a compelling opportunity for institutional investors in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $22.57M |
| Gross Profit (TTM) | $22.57M |
| EBITDA | $-214.95M |
| Operating Margin | -1922.00% |
| Return on Equity | -29.50% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.70 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | 0 |
| Float | $80.70M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
78.88%
HV 20-Day
66.41%
HV 30-Day
76.46%
HV 60-Day
98.60%
HV Rank
13.5%
Volatility is currently expanding
Data last updated: 7/9/2026